Replimune Group Stock Pattern Recognition Hikkake Pattern
| REPL Stock | USD 7.14 -0.44 -5.80% |
| Symbol |
Recognition |
This analysis covers fifty-six data points across the selected time horizon. The function generated a total of nine valid pattern recognition events for the selected time horizon. The Hikkake pattern is used for determining Replimune market turning-points and continuations.
Replimune Technical Analysis Modules
Most technical analysis of Replimune help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Replimune from various momentum indicators to cycle indicators. When you analyze Replimune charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Stock Overview, Methodology & Data Sources
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts. Replimune operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 206 people. A high-level view of Replimune emphasizes earnings durability, balance-sheet flexibility, and competitive positioning. Current metrics include P/B of 2.8. Replimune has a market cap of 589.57 M, ROE of -90.88%.
Methodology
Unless otherwise specified, financial data for Replimune Group is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Replimune (USA Stocks:REPL) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Information for Replimune Group is compiled from public filings and market reference sources and official sources including U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Reporting latency may occur in some cases. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Replimune Group may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
This content is curated and reviewed by:
Ellen Johnson - Member of Macroaxis Editorial BoardBecome your own money manager
A reliable portfolio-monitoring process is important because investors need to see whether Replimune Group is improving total return without quietly increasing concentration or risk. This is most helpful when investors want a consistent framework for balancing conviction with risk control.
Did you try this?
Run Insider Screener Now
Insider ScreenerFind insiders across different sectors to evaluate their impact on performance |
| All Next | Launch Module |
Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Adviser Favorites Invested few shares | |
 | Macroaxis Index Invested over 60 shares | |
 | Dividend Beast Invested over 40 shares | |
 | Corona Opportunity Invested few shares | |
 | Warren Buffett Holdings Invested over 20 shares | |
 | Artificial Intelligence Invested few shares | |
 | Hedge Favorites Invested few shares | |
 | Driverless Cars Invested few shares | |
 | FinTech Invested over 20 shares | |
 | ESG Investing Invested few shares |
More Resources for Replimune Stock Analysis
Understanding Replimune Group typically begins with financial statements and long-term trend review. Replimune's financial ratios translate raw accounting data into comparable profitability and efficiency signals. Selected reports below provide context for Replimune Stock:Replimune has a market cap of 589.57 M, ROE of -90.88%. Use Your Equity Center to explore allocation context. This includes a position in Replimune Group within the allocation view. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation. Replimune currently shows ROE of -90.88%, market cap of 589.57 Million. This analysis of Replimune works best as a complementary layer when evaluating how the security fits in a broader portfolio. The supplemental views below help investors decide how Replimune complements or overlaps with existing portfolio holdings. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
The market value of Replimune Group is measured differently than book value, which reflects Replimune accounting equity. Replimune's market capitalization is 589.57 M. A P/B ratio of 2.8 indicates the market values Replimune above its accounting book value. Enterprise value stands at 397.6 M. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Valuation methods compare these perspectives to frame context.
Note that Replimune's intrinsic value and market price are different measures derived from different inputs. For Replimune, key inputs include a P/B ratio of 2.8, and ROE of -90.88%. The quoted Replimune price is the exchange level where supply meets demand.